var data={"title":"Vitamin D3 (cholecalciferol): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Vitamin D3 (cholecalciferol): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5891?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=vitamin-d3-cholecalciferol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Vitamin D3 (cholecalciferol): Patient drug information&quot;</a> and <a href=\"topic.htm?path=vitamin-d3-cholecalciferol-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Vitamin D3 (cholecalciferol): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150802\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Aqueous Vitamin D [OTC];</li>\n      <li>Bio-D-Mulsion Forte [OTC] [DSC];</li>\n      <li>Bio-D-Mulsion [OTC] [DSC];</li>\n      <li>BProtected Pedia D-Vite [OTC];</li>\n      <li>D-3-5 [OTC];</li>\n      <li>D-Vi-Sol [OTC];</li>\n      <li>D-Vita [OTC] [DSC];</li>\n      <li>D3-50 [OTC];</li>\n      <li>Decara [OTC];</li>\n      <li>Delta D3 [OTC];</li>\n      <li>Dialyvite Vitamin D 5000 [OTC];</li>\n      <li>Dialyvite Vitamin D3 Max [OTC];</li>\n      <li>Pronutrients Vitamin D3 [OTC];</li>\n      <li>Vitamin D3 Super Strength [OTC];</li>\n      <li>Vitamin D3 Ultra Potency [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150803\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>D-Vi-Sol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150827\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Vitamin D Analog</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150804\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vitamin D deficiency prevention:</b> Oral: 1,500 to 2,000 units daily to maintain serum 25(OH)D levels &gt;30 ng/mL (Holick 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vitamin D deficiency treatment:</b> Oral: 6,000 units daily or 50,000 units once weekly for 8 weeks to achieve serum 25(OH)D level &gt;30 ng/mL, followed by maintenance dose of 1,500 to 2,000 units daily (Holick 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Special populations (obese patients, patients on medications known to affect vitamin D metabolism, patients with malabsorption syndromes): 6,000 to 10,000 units daily to achieve a 25(OH)D level &gt;30 ng/mL; then maintenance dose of 3,000 to 6,000 units daily (Holick 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteoporosis prevention (off-label):</b> Adults &ge;50 years: Oral: 800 to 1,000 units/day (NOF guidelines 2014)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12888900\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=vitamin-d3-cholecalciferol-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Vitamin D3 (cholecalciferol): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;\">\n      <b>Prevention of vitamin D deficiency:</b> (Greer 2000; Wagner 2008): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Breast-fed infants (fully or partially): 400 units/day beginning in the first few days of life. Continue supplementation until infant is weaned to &ge;1,000 mL/day or 1 quart/day of vitamin D-fortified formula or whole milk (whole milk should not be used until after 12 months of age)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Formula-fed infants ingesting &lt;1,000 mL of vitamin D-fortified formula: 400 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children ingesting &lt;1,000 mL of vitamin D-fortified milk: 400 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children with increased risk of vitamin D deficiency (chronic fat malabsorption, maintained on chronic antiseizure medications): Higher doses may be required; use laboratory testing 25(OH)D, PTH, bone mineral status to evaluate</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents without adequate intake: 400 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Treatment of vitamin D deficiency:</b> Oral: <b>Note:</b> In addition to calcium and phosphorus supplementation (Holick 2011; Golden 2014):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants: 2,000 units daily or 50,000 units once weekly for 6 weeks to achieve a serum 25(OH)D level &gt;20 ng/mL; followed by a maintenance dose of 400 to 1,000 units daily. <b>Note:</b> For patients at high risk of fractures a serum 25(OH)D level &gt;30 ng/mL has been suggested (Golden 2014); some organizations suggest a serum 25(OH)D level &gt;30 ng/mL should be used for all patients (Holick 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents: 2,000 units daily or 50,000 units once weekly for 6 to 8 weeks to achieve serum 25(OH)D level &gt;20 ng/mL; followed by a maintenance dose of 600 to 1,000 units daily. <b>Note:</b> For patients at high risk of fractures a serum 25(OH)D level &gt;30 ng/mL has been suggested (Golden 2014); some organizations suggest a serum 25(OH)D level &gt;30 ng/mL should be used for all patients (Holick 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children with increased risk of vitamin D deficiency (chronic fat malabsorption, maintained on chronic antiseizure medications, glucocorticoids, HIV medications and antifungals such as ketoconazole, obesity): Higher doses (2 to 3 times higher) may be required; doses of at least 6,000 to 10,000 units daily have been suggested (Holick 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> If poor compliance, single high-dose administration (100,000 to 600,000 units over 1 to 5 days) followed by maintenance dosing; intermittently repeating (usually every 3 months) may be needed if poor compliance continues with maintenance dosing (Misra 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Treatment of vitamin D insufficiency or deficiency associated with CKD (stages 2 to 5, 5D); serum 25 hydroxyvitamin D [25(OH)D] level &le;30 ng/mL</b> (KDOQI Guidelines 2009): Oral: Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Serum 25(OH)D level 16 to 30 ng/mL: 2,000 units/day for 3 months or 50,000 units every month for 3 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Serum 25(OH)D level 5 to 15 ng/mL: 4,000 units/day for 12 weeks or 50,000 units every other week for 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Serum 25(OH)D level &lt;5 ng/mL: 8,000 units/day for 4 weeks then 4,000 units/day for 2 months for total therapy of 3 months or 50,000 units/week for 4 weeks followed by 50,000 units 2 times/month for a total therapy of 3 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance dose [once repletion accomplished; serum 25(OH)D level &gt;30 ng/mL]: 200 to 1,000 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention and treatment of vitamin D Deficiency in cystic fibrosis:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>CF guidelines (Tangricha [CF Foundation] 2012):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Recommended daily intake to maintain serum 25(OH)D level &ge;30 ng/mL:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants: 400 to 500 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &le;10 years: 800 to 1,000 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &gt;10 years and Adolescents: 800 to 2,000 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dosing adjustment for serum 25(OH)D level between 20 to 30 ng/mL and patient adherence established (Step 1 increase):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants: 800 to 1,000 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &le;10 years: 1,600 to 3,000 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &gt;10 years and Adolescents: 1,600 to 6,000 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dosing adjustment for serum 25(OH)D level &lt;20 ng/mL or persistently between 20 to 30 ng/mL and patient adherence established (Step 2):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants: Increase up to a maximum of 2,000 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &le;10 years: Increase to a maximum of 4,000 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &gt;10 years and Adolescents: Increase to a maximum of 10,000 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate dosing (Hall 2010):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial dose: Serum 25(OH)D level &le;30 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants: 8,000 units/<b>week</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents: 800 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Medium-dose regimen: Serum 25(OH)D level remains &le;30 ng/mL and patient compliance established</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children &lt;5 years: 12,000 units/week for 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;5 years and Adolescents: 50,000 units/week for 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">High-dose regimen: Repeat 25(OH)D level remains &le;30 ng/mL and patient compliance established</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children &lt;5 years: 12,000 units twice weekly for 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;5 years and Adolescents: 50,000 units twice weekly for 12 weeks</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150805\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">&le;70 years: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22903598\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22903599\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150796\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">D3-50: 50,000 units [dairy free, egg free, fish derivative free, gluten free, kosher certified, no artificial color(s), nut free, soy free, sugar free, wheat free, yeast free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Decara: 10,000 units [contains fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 aluminum lake, gelatin (bovine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Decara: 25,000 units [contains soybean oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Decara: 50,000 units [contains fd&amp;c yellow #10 (quinoline yellow), fd&amp;c yellow #6 (sunset yellow), soybean oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dialyvite Vitamin D 5000: 5000 units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pronutrients Vitamin D3: 1000 units [contains soybean oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10,000 units, 50,000 units</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">D-3-5: 5000 units [dairy free, dye free, egg free, gluten free, no artificial color(s), nut free, soy free, sugar free, wheat free, yeast free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">D3-50: 50,000 units [dairy free, egg free, fish derivative free, gluten free, kosher certified, no artificial color(s), nut free, soy free, sugar free, wheat free, yeast free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2000 units, 5000 units, 10,000 units</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Liquid, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aqueous Vitamin D: 400 units/mL (50 mL) [gluten free, lactose free, sugar free; contains methylparaben, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bio-D-Mulsion: 400 units/0.03 mL (30 mL [DSC]) [contains sesame oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bio-D-Mulsion Forte: 2000 units/0.03 mL (30 mL [DSC]) [contains sesame oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">BProtected Pedia D-Vite: 400 units/mL (50 mL) [alcohol free, sugar free; contains polysorbate 80, propylene glycol, sodium benzoate; cherry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">D-Vi-Sol: 400 units/mL (50 mL) [gluten free, lactose free, sugar free; contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">D-Vita: 400 units/mL (50 mL [DSC]) [alcohol free, gluten free, lactose free, sugar free; contains polysorbate 80, propylene glycol, sodium benzoate; fruit flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 400 units/mL (50 mL, 52.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Liquid, Oral [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5000 units/mL (52.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Delta D3: 400 units [gelatin free, gluten free, lactose free, no artificial color(s), no artificial flavor(s), starch free, sugar free, yeast free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dialyvite Vitamin D3 Max: 50,000 units [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vitamin D3 Super Strength: 2000 units [gluten free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vitamin D3 Ultra Potency: 50,000 units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 400 units, 1000 units, 2000 units, 3000 units, 5000 units</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 400 units, 1000 units, 2000 units, 5000 units</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Chewable, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 400 units</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150785\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46283825\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Wafers: Chew or crush before swallowing; do not swallow wafer whole; administer with the largest meal of the day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infant drops: Administer with syringe directly into mouth (tip against the inside of cheek) or mix with formula, juice, cereal, or other food and use within 1 hour. Liquid vitamin D preparations have the potential for dosing errors when administered to infants. The FDA recommends using a calibrated dropper that delivers no more than 400 units per dose for products intended for infants.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150797\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dietary supplement:</b> As a vitamin D dietary supplement</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vitamin D deficiency:</b> Prevention and treatment of vitamin D deficiency</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25722021\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Osteoporosis (prevention)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10303065\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cholecalciferol may be confused with alfacalcidol, ergocalciferol</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Liquid vitamin D preparations have the potential for dosing errors when administered to infants. Droppers should be clearly marked to easily provide 400 international units. For products intended for infants, the FDA recommends that accompanying droppers deliver no more than 400 international units per dose.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150790\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">No adverse reactions listed in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150799\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OTC labeling: Replesta products only: When used for self-medication, do not use if you have hypercalcemia, primary hyperparathyroidism, sarcoidosis, hypervitaminosis D, Williams syndrome, or are pregnant.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Documentation of allergenic cross-reactivity for vitamin D is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46283820\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vitamin D toxicity: May occur with excessive doses; symptoms may include nausea, vomiting, loss of appetite, constipation, dehydration, fatigue, irritability, confusion, weakness and/or weight loss. Effects of vitamin D can last &ge;2 months after therapy is discontinued.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: May be at greater risk of vitamin D toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: May be at greater risk of vitamin D toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol;  large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse  (AAP 1997; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Zar 2007). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Obesity: Adults with a BMI &gt;30 kg/m<sup>2</sup> are at high risk for vitamin D deficiency due to storage of vitamin D in adipose tissue. Doses higher than the RDA may be required, but must be carefully monitored to avoid toxicity (Holick 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150824\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> CYP2C9 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150791\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10117&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aluminum Hydroxide: Vitamin D Analogs may increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Management: Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (eg, cholestyramine). Separate administration of these agents by several hours to minimize the potential risk of interaction. Monitor plasma calcium concentrations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Vitamin D Analogs may enhance the arrhythmogenic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Danazol: May enhance the hypercalcemic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mineral Oil: May decrease the serum concentration of Vitamin D Analogs. More specifically, mineral oil may interfere with the absorption of Vitamin D Analogs. Management: Avoid concomitant, oral administration of mineral oil and vitamin D analogs. Consider separating the administration of these agents by several hours to minimize the risk of interaction. Monitor plasma calcium concentrations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Vitamin D Analogs. More specifically, orlistat may impair absorption of Vitamin D Analogs. Management: Monitor clinical response (including serum calcium) to oral vitamin D analogs closely if used with orlistat.  If this combination must be used, consider giving the vitamin D analog at least 2 hrs before or after orlistat.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucralfate: Vitamin D Analogs may increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May enhance the hypercalcemic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin D Analogs: May enhance the adverse/toxic effect of other Vitamin D Analogs.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13861968\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">The cholecalciferol metabolite, 25(OH)D, crosses the placenta; maternal serum concentrations correlate with fetal concentrations at birth (Misra 2008; Wagner 2008). Vitamin D requirements are the same in pregnant and nonpregnant females (IOM 2011).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Vitamin D deficiency in a pregnant woman may lead to a vitamin D deficiency in the neonate (Misra 2008; Wagner 2008). Serum 25(OH)D concentrations should be measured in pregnant women considered to be at increased risk of deficiency (ACOG 2011). The amount of vitamin D contained in prenatal vitamins may not be adequate to treat a deficiency during pregnancy; although larger doses may be needed, current guidelines recommend a total of 1,000 to 2,000 units/day until more safety data is available (ACOG 2011; Holick 2011). In women not at risk for deficiency, doses larger than the RDA should be avoided during pregnancy (ACOG 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7310085\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">The 25(OH)D metabolite can be detected in breast milk. Small quantities of vitamin D are found in breast milk following normal maternal exposure via sunlight and diet. Maternal vitamin D requirements are the same for nursing and non-nursing women. However, the amount of vitamin D in breast milk does not correlate with serum concentrations in the infant. In addition, premature infants, infants born to vitamin D deficient mothers, dark skinned children, children living at high latitudes, and exclusively breast-fed infants and children may be at increased risk for vitamin D deficiency. Therefore, vitamin D supplementation is recommended in all infants who are partially or exclusively breast fed (IOM 2011; Misra 2008; Wagner 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46283824\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Vitamin D is found in egg yolks, fatty fish, fortified milk, fortified cereal, and infant formulas; it is also produced by exposure to sunlight (IOM, 2011).</p>\n    <p style=\"text-indent:0em;\">\n      <b>Dietary Reference Intake for Vitamin D (IOM 2011):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">0 to 12 months: Adequate intake: 400 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1 to 70 years: RDA: 600 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;70 years: RDA: 800 units/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pregnancy/Lactating: RDA: 600 units/day</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46283827\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Signs and symptoms of vitamin D intoxication.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum 25(OH)D should be monitored in patients at risk for vitamin D deficiency; Serum 1,25-dihydroxyvitamin D may be used in conditions such as acquired or inherited vitamin D disorders (eg, chronic kidney disease, vitamin D resistant rickets) or phosphate metabolism (Holick 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">When treating vitamin D deficiency in children, monitor serum calcium, phosphorus and alkaline phosphatase (ALP) one month after starting therapy; serum calcium, phosphorous, magnesium, ALP, 25(OH)D, and PTH as well as x-ray (may also consider urine calcium/creatinine ratio) after 3 months; 25(OH)D yearly (Misra 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children at increased risk of vitamin D deficiency (chronic fat malabsorption, chronic antiseizure medication use) require serum 25(OH)D, PTH, and bone mineral status to evaluate. If vitamin D supplement required, then 25(OH)D levels should be repeated at 3-month intervals until normal. PTH and bone mineral status should be monitored every 6 months until normal. (Wagner 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin D deficiency/insufficiency in patients with CKD stages 3 to 4: Measure serum 25(OH)D levels after 3 months of treatment in children or after 6 months in adults. Measure corrected total calcium and phosphorous after 1 month and then at least every 3 months in children and at least every 3 months in adults. Discontinue ergocalciferol (or any vitamin D supplements) if the corrected total serum calcium level is &gt;10.2 mg/dL (K/DOQI 2003; K/DOQI 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum 25(OH)D in patients on long term anticonvulsant medications, antifungals, cholestyramine, glucocorticoids, or medications to treat HIV; the catabolism of the metabolite 25(OH)D may be increased (Holick 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7310086\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum calcium times phosphorus should not exceed 70 mg<sup>2</sup>/dL<sup>2</sup> to avoid ectopic calcification</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin D deficiency: There is no clear consensus on a reference range for total serum 25(OH)D concentrations or the validity of this level as it relates clinically to bone health. In addition, there is significant variability in the reporting of serum 25 (OH)D levels as a result of different assay types in use. However, the following ranges have been suggested:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults (IOM 2011):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;12 ng/mL (30 nmol/L): At risk for deficiency</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">12 to 20 ng/mL (30 to 50 nmol/L): Potentially at risk for inadequacy </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;20 ng/mL (50 nmol/L): Sufficient levels in practically all persons</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;50 ng/mL (125 nmol/L): Concern for risk of toxicity</p>\n    <p style=\"text-indent:-4em;margin-left:6em;margin-right:4em;\">Osteoporosis patients (NOF [Cosman 2014]): ~30 ng/mL (75 nmol/L): Recommended level to reach and maintain</p>\n    <p style=\"text-indent:-4em;margin-left:6em;margin-right:4em;\">Children (Misra 2008):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;15 ng/mL (37.5 nmol/L): At risk for deficiency</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">15 to 20 ng/mL (37.5 to 50 nmol/L): Potentially at risk for inadequacy</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;20 ng/mL (50 nmol/L): Sufficient levels in practically all children</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;100 ng/mL (250 nmol/L): Concern for risk of toxicity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46283822\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Cholecalciferol (vitamin D<sub>3</sub>) is a provitamin. The active metabolite, 1,25-dihydroxyvitamin D (calcitriol), stimulates calcium and phosphate absorption from the small intestine, promotes secretion of calcium from bone to blood; promotes renal tubule phosphate resorption (IOM 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F595885\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;\">Absorption: Absorbed in the small intestine; fat soluble; requires bile (IOM 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Inactive until hydroxylated hepatically to 25-hydroxyvitamin D [25(OH)D; calcifediol] then renally to the active metabolite 1,25-dihydroxyvitamin D (calcitriol) (IOM 2011)</p>\n    <p style=\"text-indent:0em;\">Half-life, circulating: 25(OH)D: 2 to 3 weeks; 1,25-dihydroxyvitamin D: ~4 hours (Holick 2011)</p>\n    <p style=\"text-indent:0em;\">Excretion: Feces (IOM 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323065\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (D3-50 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50000 unit (100): $20.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Decara Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10000 unit (50): $40.14</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25000 unit (30): $57.39</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50000 unit (50): $58.68</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Dialyvite Vitamin D 5000 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5000 unit (90): $11.06</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Pronutrients Vitamin D3 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (120): $8.63</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (BProtected Pedia D-Vite Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 units/mL (50 mL): $8.29</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (D-Vi-Sol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 units/mL (50 mL): $8.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Dialyvite Vitamin D3 Max Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50000 unit (12): $12.91</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Vitamin D Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (100): $2.85</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150800\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adalben (ES);</li>\n      <li>Arachitol (IN);</li>\n      <li>Aviticol (GB);</li>\n      <li>Baby D Drops (SG);</li>\n      <li>D Drops (SG);</li>\n      <li>D-Cure (BE, LU);</li>\n      <li>D3 Capsules (AU);</li>\n      <li>D3 Drops (AU);</li>\n      <li>D3 Drops Forte (AU);</li>\n      <li>D4U (LK);</li>\n      <li>Deetipat (FI);</li>\n      <li>Dekristol 400 (DE);</li>\n      <li>Dekristolmin (AT);</li>\n      <li>Deltius (ES);</li>\n      <li>Desunin (GB);</li>\n      <li>Devaron (NL);</li>\n      <li>Devitre (SE);</li>\n      <li>Duvit D3 (IT);</li>\n      <li>Fultium-D3 (GB);</li>\n      <li>Iper D3 (IT);</li>\n      <li>Laevovit (HU);</li>\n      <li>Laevovit D3 (AT);</li>\n      <li>Ostelavit (PL);</li>\n      <li>Plivit D3 (HR);</li>\n      <li>Teorol (ID);</li>\n      <li>Tridelta (IT);</li>\n      <li>Uvedose (FR, LU);</li>\n      <li>Vi-De 3 (CH);</li>\n      <li>Vigantol (CZ, HU, LU, PL, PT);</li>\n      <li>Vigantoletten (LU, PL);</li>\n      <li>Vitamin D3 (HU);</li>\n      <li>Vitamin D3 Fresenius (HU);</li>\n      <li>Vitamin D3 Streuli (CH);</li>\n      <li>Vitamine D3 BON (FR);</li>\n      <li>Vitaminum D3 (PL);</li>\n      <li>Vitamon D3 (BE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Obstetric Practice. ACOG Committee Opinion No. 495: Vitamin D: Screening and supplementation during pregnancy. <i>Obstet Gynecol</i>. 2011;118(1):197-198. doi: 10.1097/AOG.0b013e318227f06b.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d3-cholecalciferol-drug-information/abstract-text/21691184/pubmed\" target=\"_blank\" id=\"21691184\">21691184</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d3-cholecalciferol-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d3-cholecalciferol-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d3-cholecalciferol-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bio-D-Mulsion (cholecalciferol) [prescribing information]. Rosenberg, TX: Biotics Research; July 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bio-D-Mulsion Forte (cholecalciferol) [prescribing information]. Rosenberg, TX: Biotics Research; July 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d3-cholecalciferol-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d3-cholecalciferol-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cosman F, de Beur SJ, LeBoff MS, et al; National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. <i>Osteoporos Int</i>. 2014;25(10):2359-2381.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d3-cholecalciferol-drug-information/abstract-text/25182228/pubmed\" target=\"_blank\" id=\"25182228\">25182228</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    D1000 Capsules (cholecalciferol) [prescribing information]. Miami Lakes, FL: Mason Vitamins; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    D2000 Capsules (cholecalciferol) [prescribing information]. Miami Lakes, FL: Mason Vitamins; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    D5000 Capsules (cholecalciferol) [prescribing information]. Miami Lakes, FL: Mason Vitamins; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    D400 Chewable Tablets (cholecalciferol) [prescribing information]. Miami Lakes, FL: Mason Vitamins; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    D1000 Chewable Tablets (cholecalciferol) [prescribing information]. Miami Lakes, FL: Mason Vitamins; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Decara 25,000 IU Capsules (cholecalciferol) [prescribing information]. Baton Rouge, LA; Medecor Pharma LLC; February 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Decara 50,000 IU Capsules (cholecalciferol) [prescribing information]. Baton Rouge, LA: Medecor Pharma LLC; February 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    D-Vi-Sol (cholecalciferol) [prescribing information]. Evansville, IN: Mead Johnson Nutritionals; November 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Golden NH, Abrams SA; Committee on Nutrition. Optimizing bone health in children and adolescents. <i>Pediatrics</i>. 2014;134(4):e1229-1243.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d3-cholecalciferol-drug-information/abstract-text/25266429/pubmed\" target=\"_blank\" id=\"25266429\">25266429</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greer FR. Vitamin metabolism and requirements in the micropremie. Clin Perinatol. 2000;27(1):95-118, vi. Review.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d3-cholecalciferol-drug-information/abstract-text/10690566/pubmed\" target=\"_blank\" id=\"10690566\">10690566</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hall WB, Sparks AA, Aris RM. Vitamin d deficiency in cystic fibrosis. <i>Int J Endocrinol</i>. 2010;2010:218691.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d3-cholecalciferol-drug-information/abstract-text/20148079 /pubmed\" target=\"_blank\" id=\"20148079 \">20148079 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Holick MF, Binkley NC, Bischoff-Ferrari HA, et al; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2011;96(7):1911-1930.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d3-cholecalciferol-drug-information/abstract-text/21646368/pubmed\" target=\"_blank\" id=\"21646368\">21646368</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine), <i>Dietary Reference Intakes for Calcium and Vitamin D</i>, Washington, DC: The National Academies Press, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d3-cholecalciferol-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    KDOQI Work Group. KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 Update. Executive Summary. <i>Am J Kidney Dis</i>. 2009;53(3 Suppl 2):S11-104.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d3-cholecalciferol-drug-information/abstract-text/19231749/pubmed\" target=\"_blank\" id=\"19231749\">19231749</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d3-cholecalciferol-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Misra M, Pacaud D, Petryk A, et al, &quot;Vitamin D Deficiency in Children and Its Management: Review of Current Knowledge and Recommendations,&quot; <i>Pediatrics</i>, 2008, 122(2):398-417.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d3-cholecalciferol-drug-information/abstract-text/18676559/pubmed\" target=\"_blank\" id=\"18676559\">18676559</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. <i>Am J Kidney Dis</i>. 2005;46(4 Suppl 1):S1-S121.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. <i>Am J Kidney Dis</i>. 2003;42(4 Suppl 3):S1-S201.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d3-cholecalciferol-drug-information/abstract-text/14520607/pubmed\" target=\"_blank\" id=\"14520607\">14520607</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pedia D-Vite Drops (cholecalciferol) [prescribing information]. Tampa, FL: Bayshore Pharmaceuticals; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Replesta (cholecalciferol) [prescribing information]. St. Louis, MO: Everidis Health Sciences; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Replesta Children&rsquo;s (cholecalciferol) [prescribing information]. St. Louis, MO: Everidis Health Sciences; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Replesta NX (cholecalciferol) [prescribing information]. St. Louis, MO: Everidis Health Sciences; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d3-cholecalciferol-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thera-D Sport (cholecalciferol) [prescribing information]. Rockville, MD: Theralogix; received September 3, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wagner CL, Greer FR; American Academy of Pediatrics Section on Breastfeeding; American Academy of Pediatrics Committee on Nutrition. Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. <i>Pediatrics</i>. 2008;122(5):1142-1152. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d3-cholecalciferol-drug-information/abstract-text/18977996/pubmed\" target=\"_blank\" id=\"18977996\">18977996</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-d3-cholecalciferol-drug-information/abstract-text/17555487/pubmed\" target=\"_blank\" id=\"17555487\">17555487</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10117 Version 182.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F150802\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F150803\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F150827\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F150804\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F12888900\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F150805\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22903598\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22903599\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F150796\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F150785\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F46283825\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F150797\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25722021\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F10303065\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F150790\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F150799\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F46283820\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F150824\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F150791\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13861968\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F7310085\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F46283824\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F46283827\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F7310086\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F46283822\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F595885\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323065\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F150800\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10117|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=vitamin-d3-cholecalciferol-patient-drug-information\" class=\"drug drug_patient\">Vitamin D3 (cholecalciferol): Patient drug information</a></li><li><a href=\"topic.htm?path=vitamin-d3-cholecalciferol-pediatric-drug-information\" class=\"drug drug_pediatric\">Vitamin D3 (cholecalciferol): Pediatric drug information</a></li></ul></div></div>","javascript":null}